ciclopirox has been researched along with Nail Fungus in 102 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ciclopirox 8% hydrolacquer is more active than reference ciclopirox nail lacquer in the treatment of onychomycosis." | 9.14 | An innovative water-soluble biopolymer improves efficacy of ciclopirox nail lacquer in the management of onychomycosis. ( Altmeyer, P; Baran, R; Combemale, P; Hartmane, I; Hercogova, J; Koudelkova, V; Mikazans, I; Ruzicka, T; Tosti, A, 2009) |
| "To evaluate the efficacy of a combination therapy of ciclopirox nail lacquer and oral terbinafine compared to oral terbinafine monotherapy for the treatment of onychomycosis caused by dermatophytes." | 9.11 | Combination of oral terbinafine and topical ciclopirox compared to oral terbinafine for the treatment of onychomycosis. ( Avner, S; Henri, T; Nir, N, 2005) |
| "This multicenter, open-label, uncontrolled, noncomparative, observational, postmarketing study assessed the efficacy and safety of ciclopirox nail lacquer solution 8% in 3666 patients for the treatment of onychomycosis." | 9.09 | A multicenter, open-label study of the efficacy and safety of ciclopirox nail lacquer solution 8% for the treatment of onychomycosis in patients with diabetes. ( Nietsch, KH; Seebacher, C; Ulbricht, HM, 2001) |
| "Ciclopirox nail lacquer solution 8%, effective and safe for the treatment of dermatophyte onychomycosis of mild-to-moderate severity, covers a broad-spectrum of organisms and also may be effective in onychomycosis caused by Candida species and nondermatophyte molds." | 8.81 | Ciclopirox nail lacquer: a brush with onychomycosis. ( Gupta, AK, 2001) |
| "Ciclopirox nail lacquer solution 8% is a recent addition to the armamentarium of therapies available to the physician and patient for the treatment of onychomycosis." | 8.80 | Pharmacoeconomic analysis of ciclopirox nail lacquer solution 8% and the new oral antifungal agents used to treat dermatophyte toe onychomycosis in the United States. ( Gupta, AK, 2000) |
| "Data from the pivotal US trials have demonstrated that ciclopirox nail lacquer 8% topical solution is significantly more effective than placebo in the treatment of onychomycosis caused by Trichophyton rubrum, and of mild to moderate toe onychomycosis without lunula involvement." | 8.80 | Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis. ( Baran, R; Fleckman, P; Gupta, AK, 2000) |
| "We report a case of proximal fold cellulitis in both big toes, associated with a bilateral proximal onychomycosis and an intertrigo of the fourth space due to Fusarium solani." | 7.73 | [Bilateral proximal cellulitis and onychomycosis in both big toes due to Fusarium solani]. ( Sellart-Altisent, M; Torres-Rodríguez, JM, 2006) |
| " Its antifungal activity has been compared to ciclopiroxolamine and sulconazole, commonly used in onychomycosis treatment and chosen because of their very different chemical structures." | 7.70 | Use of caryophyllene oxide as an antifungal agent in an in vitro experimental model of onychomycosis. ( Chaumont, JP; Michel, L; Millet-Clerc, J; Yang, D, 1999) |
| " Nail avulsion followed by long-term occlusive application of ciclopiroxolamine cleared the onychomycosis, whereas the sole and palm infection was resistant to ciclopiroxolamine and glutaraldehyde treatment." | 7.67 | Hendersonula toruloidea infection: successful response of onychomycosis to nail avulsion and topical ciclopiroxolamine. ( Johansson, S; Rollman, O, 1987) |
| "Onychomycosis is prevalent in the Canadian population, and risk factors, such as old age and diabetes, are increasing." | 6.43 | Ciclopirox nail lacquer 8% for the treatment of onychomycosis: a Canadian perspective. ( Gupta, AK; Lynch, LE; Schouten, JR, 2005) |
| "Ciclopirox has been formulated in a nail lacquer delivery system." | 6.41 | Dermatopharmacology of ciclopirox nail lacquer topical solution 8% in the treatment of onychomycosis. ( Bohn, M; Kraemer, KT, 2000) |
| "A new water-soluble formulation for a ciclopirox nail lacquer showed similar efficacy to the reference product to eradicate toenail onychomycosis and superiority in the mycological cure defined by negative culture, thus preventing reinfections and recurrences." | 5.69 | Efficacy and safety of a new medicated nail hydrolacquer in the treatment of adults with toenail onychomycosis: A randomised clinical trial. ( Bermejo, R; Briones, VG; Campos, FF; Corrales, A; Igea, SA; Martínez, H; Nieto, C; Otero-Espinar, FJ; Picas, J; Zalacain-Vicuña, AJ, 2023) |
| "Onychomycosis is a relatively common disease accounting for up to 50% of all nail disorders." | 5.36 | Ciclopirox nail lacquer for the treatment of onychomycosis: an open non-comparative study. ( Amichai, B; Grunwald, MH; Nathansohn, N; Shemer, A; Trau, H, 2010) |
| "Efinaconazole topical solution 10% and tavaborole topical solution 5% are FDA approved for the treatment of onychomycosis in children ≥6 years; ciclopirox topical solution 8% nail lacquer is approved in children ≥12 years." | 5.22 | Onychomycosis in children - review on treatment and management strategies. ( Gupta, AK; Piguet, V; Shear, NH; Venkataraman, M, 2022) |
| "A treatment of onychomycosis comprising chemical avulsion of the pathological nail, ciclopirox cream and nail lacquer is significantly more effective than amorolfine nail lacquer." | 5.17 | A multicenter, randomized, open-label, controlled study comparing the efficacy, safety and cost-effectiveness of a sequential therapy with RV4104A ointment, ciclopiroxolamine cream and ciclopirox film-forming solution with amorolfine nail lacquer alone in ( Ben Osman, A; Bienvenu, AL; Bulai-Livideanu, C; Cazeau, C; Coubetergues, H; Coustou, D; Doss, N; Fazaa, B; Lahfa, M; Mokthar, I; Nouira, R; Paul, C; Picot, S; Turki, H; Voisard, JJ; Zourabichvili, O, 2013) |
| "Ciclopirox 8% hydrolacquer is more active than reference ciclopirox nail lacquer in the treatment of onychomycosis." | 5.14 | An innovative water-soluble biopolymer improves efficacy of ciclopirox nail lacquer in the management of onychomycosis. ( Altmeyer, P; Baran, R; Combemale, P; Hartmane, I; Hercogova, J; Koudelkova, V; Mikazans, I; Ruzicka, T; Tosti, A, 2009) |
| "To evaluate the efficacy of a combination therapy of ciclopirox nail lacquer and oral terbinafine compared to oral terbinafine monotherapy for the treatment of onychomycosis caused by dermatophytes." | 5.11 | Combination of oral terbinafine and topical ciclopirox compared to oral terbinafine for the treatment of onychomycosis. ( Avner, S; Henri, T; Nir, N, 2005) |
| "This multicenter, open-label, uncontrolled, noncomparative, observational, postmarketing study assessed the efficacy and safety of ciclopirox nail lacquer solution 8% in 3666 patients for the treatment of onychomycosis." | 5.09 | A multicenter, open-label study of the efficacy and safety of ciclopirox nail lacquer solution 8% for the treatment of onychomycosis in patients with diabetes. ( Nietsch, KH; Seebacher, C; Ulbricht, HM, 2001) |
| "60 patients, suffering from an onychomycosis produced by molds were treated for a maximum of 6 months with ciclopirox nail lacquer (8%)." | 5.07 | [Therapy with ciclopirox lacquer of onychomycoses caused by molds]. ( Ulbricht, H; Wörz, K, 1994) |
| "Terbinafine is an excellent choice in diabetics due to its low risk of drug-drug interaction and proven efficacy against the typical pathogens that cause onychomycosis." | 4.85 | Onychomycosis and diabetes. ( Cantrell, W; Cathcart, S; Elewski, Be, 2009) |
| "The management of onychomycosis using topical agents has improved with the introduction of ciclopirox and amorolfine nail lacquers; other topical agents may be less effective." | 4.82 | The use of topical therapies to treat onychomycosis. ( Baran, R; Gupta, AK; Ryder, JE, 2003) |
| "Based on the patient-level analysis, we concluded that terbinafine is the most cost-effective therapy in the treatment of onychomycosis from a managed care perspective." | 4.82 | Economic analysis of oral and topical therapies for onychomycosis of the toenails and fingernails. ( Amaya, K; Arikian, S; Casciano, J; Doyle, J; Haspel, M; Kahler, K; Shear, N, 2003) |
| " As both amorolfine and ciclopirox have proved useful as monotherapy for onychomycosis that does not involve the nail matrix area, the purpose of this article is to check if, when combined with oral agents, the effectiveness and scope of treatment can be improved further." | 4.82 | Topical antifungal drugs for the treatment of onychomycosis: an overview of current strategies for monotherapy and combination therapy. ( Baran, R; Kaoukhov, A, 2005) |
| "Ciclopirox nail lacquer solution 8%, effective and safe for the treatment of dermatophyte onychomycosis of mild-to-moderate severity, covers a broad-spectrum of organisms and also may be effective in onychomycosis caused by Candida species and nondermatophyte molds." | 4.81 | Ciclopirox nail lacquer: a brush with onychomycosis. ( Gupta, AK, 2001) |
| "Ciclopirox nail lacquer solution 8% is a recent addition to the armamentarium of therapies available to the physician and patient for the treatment of onychomycosis." | 4.80 | Pharmacoeconomic analysis of ciclopirox nail lacquer solution 8% and the new oral antifungal agents used to treat dermatophyte toe onychomycosis in the United States. ( Gupta, AK, 2000) |
| "Ciclopirox nail lacquer solution 8% has been shown to be effective in the treatment of dermatophyte onychomycosis of mild to moderate severity Other studies report the effectiveness of ciclopirox nail lacquer in onychomycosis caused by Candida sp and nondermatophyte molds." | 4.80 | Ciclopirox nail lacquer solution 8% in the 21st century. ( Baran, R; Gupta, AK, 2000) |
| "Data from the pivotal US trials have demonstrated that ciclopirox nail lacquer 8% topical solution is significantly more effective than placebo in the treatment of onychomycosis caused by Trichophyton rubrum, and of mild to moderate toe onychomycosis without lunula involvement." | 4.80 | Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis. ( Baran, R; Fleckman, P; Gupta, AK, 2000) |
| "Onychomycosis is a nail infection caused by Trichophyton interdigitale and other fungi, which can be treated with topical amorolfine (AMR) and ciclopirox olamine (CPX)." | 4.12 | Reactive oxygen and nitrogen species are crucial for the antifungal activity of amorolfine and ciclopirox olamine against the dermatophyte Trichophyton interdigitale. ( Almeida, BCT; Baltazar, LM; Carmo, PHF; Dornelas, JCM; Ferreira, GF; Freitas, GJC; Peres, NTA; Santos, DA, 2022) |
| "There currently are 3 topical agents approved by the US Food and Drug Administration (FDA) to treat onychomycosis: tavaborole, efinaconazole, and ciclopirox." | 3.85 | Clinical trial designs for topical antifungal treatments of onychomycosis and implications on clinical practice. ( Adigun, CG; Gellings Lowe, N; Hall, SB; Joseph, WS; Rich, P; Vlahovic, TC; Zane, LT, 2017) |
| "In 1996, oral terbinafine joined itraconazole and fluconazole on the short list of systemic medications that could be used to treat onychomycosis (although fluconazole was not approved for this indication by the US Food and Drug Administration [FDA], it was commonly used for this purpose)." | 3.83 | Antifungal Drugs for Onychomycosis: Efficacy, Safety, and Mechanisms of Action. ( Rosen, T; Stein Gold, LF, 2016) |
| " Tavaborole topical solution, 5% is a novel boron-based pharmaceutical approved for the treatment of toenail onychomycosis due to Trichophyton rubrum or T mentagrophytes." | 3.81 | In Vitro Nail Penetration and Antifungal Activity of Tavaborole, a Boron-Based Pharmaceutical. ( Chanda, S; Coronado, D; Merchant, T; Zane, LT, 2015) |
| " He had been treated with two courses of oral terbinafine and topical 8% ciclopirox for presumed onychomycosis." | 3.81 | Trichophytum rubrum endonyx onychomycosis resistant to standard oral and topical therapies. ( Jellinek, N; Mulvaney, PM; Telang, GH, 2015) |
| "The in vitro activities of luliconazole, amorolfine, ciclopirox, and terbinafine were determined against 320 dermatophyte isolates from large toenails of onychomycosis patients enrolled into an ongoing phase 2b/3 clinical study." | 3.80 | Luliconazole demonstrates potent in vitro activity against dermatophytes recovered from patients with onychomycosis. ( Fothergill, AW; McCarthy, DI; Tavakkol, A; Wiederhold, NP, 2014) |
| "When formulated with lipid enhancers, the amount of ciclopirox in the ventral/intermediate layer and supporting bed dramatically exceed the inhibitory concentration of ciclopirox for the most common onychomycosis organisms." | 3.80 | Ciclopirox delivery into the human nail plate using novel lipid diffusion enhancers. ( Hafeez, F; Hui, X; Maibach, H; Rosenthal, B; Selner, M, 2014) |
| "Two nail lacquers, containing ciclopirox (CPX) or amorolfine (MRF), based on water-insoluble polymers are currently considered mainstays of topical treatment of onychomycosis." | 3.76 | Hydrosoluble medicated nail lacquers: in vitro drug permeation and corresponding antimycotic activity. ( Burgalassi, S; Chetoni, P; Ghelardi, E; Mailland, F; Monti, D; Saccomani, L; Senesi, S, 2010) |
| "We report a case of proximal fold cellulitis in both big toes, associated with a bilateral proximal onychomycosis and an intertrigo of the fourth space due to Fusarium solani." | 3.73 | [Bilateral proximal cellulitis and onychomycosis in both big toes due to Fusarium solani]. ( Sellart-Altisent, M; Torres-Rodríguez, JM, 2006) |
| "A structure-activity relationship investigation for a more efficacious therapy to treat onychomycosis, a fungal infection of the toe and fingernails, led to the discovery of a boron-containing small molecule, 5-fluoro-1,3-dihydro-1-hydroxy-2,1-benzoxaborole (AN2690), which is currently in clinical trials for onychomycosis topical treatment." | 3.73 | Discovery of a new boron-containing antifungal agent, 5-fluoro-1,3-dihydro-1-hydroxy-2,1- benzoxaborole (AN2690), for the potential treatment of onychomycosis. ( Akama, T; Alley, MR; Baker, SJ; Hernandez, V; Lau, A; Mao, W; Plattner, JJ; Sanders, V; Zhang, YK; Zhou, H, 2006) |
| "Amorolfine was consistently more cost-effective in terms of weighted average daily treatment cost and cost per patient cured than ciclopirox and tioconazole, when all therapies were used as indicated to treat onychomycosis." | 3.73 | Treatment costs of three nail lacquers used in onychomycosis. ( Adjadj, L; Jäckel, A; Lambert, J; Marty, JP, 2005) |
| "Ciclopirox nail lacquer 8% (Penlac, Aventis Pharma) was approved by the US FDA in December 1999, as a component of a comprehensive management program, for use in immunocompetent patients who have mild to moderate onychomycosis of the fingers and toes without lunula involvement due to Trichophyton rubrum." | 3.70 | Ciclopirox nail lacquer topical solution 8%. ( Gupta, AK, 2000) |
| " Its antifungal activity has been compared to ciclopiroxolamine and sulconazole, commonly used in onychomycosis treatment and chosen because of their very different chemical structures." | 3.70 | Use of caryophyllene oxide as an antifungal agent in an in vitro experimental model of onychomycosis. ( Chaumont, JP; Michel, L; Millet-Clerc, J; Yang, D, 1999) |
| "Itraconazole is an effective, broad-spectrum triazole used as continuous or pulse therapy in the treatment of onychomycosis." | 3.69 | Economic evaluation of antifungal agents in the treatment of toenail onychomycosis in Germany. ( De Doncker, P; Dubois, DJ; Eggleston, A; Gupta, AK; Haneke, E; Tormans, G; Van Doorslaer, EK; Van Rossem, K, 1996) |
| " Nail avulsion followed by long-term occlusive application of ciclopiroxolamine cleared the onychomycosis, whereas the sole and palm infection was resistant to ciclopiroxolamine and glutaraldehyde treatment." | 3.67 | Hendersonula toruloidea infection: successful response of onychomycosis to nail avulsion and topical ciclopiroxolamine. ( Johansson, S; Rollman, O, 1987) |
| "Onychomycosis is a prevalent condition affecting the United States and global population." | 3.01 | Individual Article: Updated Review of Topical Pharmaceuticals and Complementary and Alternative Medications for the Treatment of Onychomycosis in Both General and Special Populations in the United States. ( Issa, NT; Kircik, L, 2023) |
| " Study B: More subjects adhered to amorolfine dosage (81." | 2.84 | Patient-reported outcomes from two randomised studies comparing once-weekly application of amorolfine 5% nail lacquer to other methods of topical treatment in distal and lateral subungual onychomycosis. ( Sarkany, M; Schaller, M; Sigurgeirsson, B, 2017) |
| "Onychomycosis is a fungal infection of the nail unit." | 2.80 | Treatment of Onychomycosis - a Clinical Study. ( Pajaziti, L; Vasili, E, 2015) |
| "The conventional treatment of onychomycosis involves oral and topical therapy." | 2.61 | Novel Drug Delivery Strategies for the Treatment of Onychomycosis. ( Dhamoon, RK; Gupta, M; Popli, H, 2019) |
| "Onychomycosis is a fungal nail infection caused by dermatophytes, nondermatophytes, and yeast, and is the most common nail disorder seen in clinical practice." | 2.61 | Onychomycosis: Treatment and prevention of recurrence. ( Lipner, SR; Scher, RK, 2019) |
| "Onychomycosis is a common and difficult-to-treat fungal infection of the nail unit that gradually leads to dystrophic changes of the nail plate and nail bed." | 2.53 | Antifungal agents for onychomycosis: new treatment strategies to improve safety. ( Chanda, S; Coronado, D; Del Rosso, J; Zane, LT, 2016) |
| "Ciclopirox was first developed for fungal skin infections and vaginal candidiasis, and is currently well established in these indications." | 2.46 | Ciclopirox: recent nonclinical and clinical data relevant to its use as a topical antimycotic agent. ( Mailland, F; Monti, D; Subissi, A; Togni, G, 2010) |
| "Onychomycosis is a frequent nail disease caused by dermatophytes, yeasts, and nondermatophyte molds." | 2.46 | Onychomycosis. ( Vera-Cabrera, L; Welsh, E; Welsh, O, 2010) |
| "In the treatment of onychomycosis, compliance and drug interactions are important considerations, as diabetic patients frequently take concomitant medications." | 2.45 | Toenail onychomycosis in diabetic patients: issues and management. ( Budihardja, D; Freund, V; Mayser, P, 2009) |
| "Onychomycosis is prevalent in the Canadian population, and risk factors, such as old age and diabetes, are increasing." | 2.43 | Ciclopirox nail lacquer 8% for the treatment of onychomycosis: a Canadian perspective. ( Gupta, AK; Lynch, LE; Schouten, JR, 2005) |
| "Topical treatment of onychomycosis, as opposed to oral therapies, offers a distinct advantage by allowing the patient to apply medication directly to the affected area, thus decreasing the potential for serious adverse events, such as drug toxicity and drug interactions." | 2.42 | Management of onychomycosis with topicals. ( Albert, SF; Weis, ZH, 2004) |
| "Ciclopirox has been formulated in a nail lacquer delivery system." | 2.41 | Dermatopharmacology of ciclopirox nail lacquer topical solution 8% in the treatment of onychomycosis. ( Bohn, M; Kraemer, KT, 2000) |
| "rubrum." | 2.40 | Childhood white superficial onychomycosis caused by Trichophyton rubrum: report of seven cases and review of the literature. ( Lucky, AW; Ploysangam, T, 1997) |
| "Ciclopirox olamine is a substituted pyridone antimycotic, unrelated to the imidazole derivatives, with activity against a broad spectrum of dermatophytes, yeasts, actinomycetes, molds, other fungi, and a variety of Gram-positive and Gram-negative bacteria." | 2.37 | Ciclopirox olamine 1% cream. A preliminary review of its antimicrobial activity and therapeutic use. ( Brogden, RN; Dawson, GW; Jue, SG, 1985) |
| "Onychomycosis affects up to 50% of patients in the older population." | 1.91 | Evaluation of the heat sensitivity of Trichophyton rubrum and Trichophyton interdigitale. ( Braun, C; Kerschnitzki, A; Mann, M; Seidel, K; Tietze, JK; Tietze, LF, 2023) |
| " There are limited data on adverse events associated with the newer topical onychomycosis drugs." | 1.56 | Retrospective analysis of adverse events with topical onychomycosis medications reported to the United States Food and Drug Administration. ( Lipner, SR; Wang, Y, 2020) |
| "Onychomycosis is a prevailing disease caused by fungal infection of nails that mostly affects athletes and the elderly." | 1.43 | Development of ciclopirox nail lacquer with enhanced permeation and retention. ( Choi, JY; Go, TG; Han, SD; Jun, JH; Kang, MH; Kim, JO; Son, MW; Thapa, RK; Yong, CS, 2016) |
| "Onychomycosis is a fungal infection mostly induced by dermatophytes such as Trichophyton rubrum." | 1.40 | Comparison of the antifungal efficacy of terbinafine hydrochloride and ciclopirox olamine containing formulations against the dermatophyte Trichophyton rubrum in an infected nail plate model. ( Müller-Goymann, CC; Täuber, A, 2014) |
| "Onychomycosis is a relatively common disease accounting for up to 50% of all nail disorders." | 1.36 | Ciclopirox nail lacquer for the treatment of onychomycosis: an open non-comparative study. ( Amichai, B; Grunwald, MH; Nathansohn, N; Shemer, A; Trau, H, 2010) |
| "Treatment with terbinafine plus ciclopiroxolamine was effective." | 1.35 | Nail infection by Aspergillus ochraceopetaliformis. ( Brasch, J; Egberts, F; Jensen, JM; Tintelnot, K; Varga, J, 2009) |
| "Onychomycosis is a challenging fungal infection to treat topically, likely due to the unique properties of the nail plate." | 1.34 | In Vitro penetration of a novel oxaborole antifungal (AN2690) into the human nail plate. ( Akama, T; Baker, SJ; Barbadillo, S; Cashmore, AK; Hold, KM; Hui, X; Maibach, HI; Plattner, JJ; Sanders, V; Wester, RC; Zhang, YK, 2007) |
| "Successful treatment of onychomycosis in the infection site depends not only on achieving the minimal inhibitory concentration (MIC) of the antifungal agent, usually determined on fresh, proliferating fungal strains, but also on the effectivity against fungal spores dormant in nail keratin." | 1.32 | Action mechanisms of modern antifungal agents and resulting problems in the management of onychomycosis. ( Seebacher, C, 2003) |
| "The successful treatment of onychomycosis requires special knowledge of the various clinical presentations, of the differential diagnosis and of recent advances in medical mycology." | 1.32 | [Onychomycosis]. ( Reinel, D, 2004) |
| "Onychomycosis is often considered only as a cosmetic diagnosis." | 1.32 | Onychomycosis: current treatment options. ( Jones, ED, 2003) |
| "This report presents original methods to assess the bioavailability of an antifungal drug from a varnish preparation in finger nails." | 1.28 | Ciclopirox nail lacquer 8%: in vivo penetration into and through nails and in vitro effect on pig skin. ( Ceschin-Roques, CG; Hänel, H; Luc, J; Michel, G; Pruja-Bougaret, SM; Vandermander, J, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (2.94) | 18.7374 |
| 1990's | 14 (13.73) | 18.2507 |
| 2000's | 38 (37.25) | 29.6817 |
| 2010's | 39 (38.24) | 24.3611 |
| 2020's | 8 (7.84) | 2.80 |
| Authors | Studies |
|---|---|
| Baker, SJ | 2 |
| Zhang, YK | 2 |
| Akama, T | 2 |
| Lau, A | 1 |
| Zhou, H | 1 |
| Hernandez, V | 1 |
| Mao, W | 1 |
| Alley, MR | 1 |
| Sanders, V | 2 |
| Plattner, JJ | 2 |
| Carmo, PHF | 1 |
| Freitas, GJC | 1 |
| Dornelas, JCM | 1 |
| Almeida, BCT | 1 |
| Baltazar, LM | 1 |
| Ferreira, GF | 1 |
| Peres, NTA | 1 |
| Santos, DA | 1 |
| Bellmann, T | 1 |
| Luber, R | 1 |
| Kischio, L | 1 |
| Karl, B | 1 |
| Pötzinger, Y | 1 |
| Beekmann, U | 1 |
| Kralisch, D | 1 |
| Wiegand, C | 1 |
| Fischer, D | 1 |
| Zalacain-Vicuña, AJ | 1 |
| Nieto, C | 1 |
| Picas, J | 1 |
| Martínez, H | 1 |
| Bermejo, R | 1 |
| Corrales, A | 1 |
| Campos, FF | 1 |
| Igea, SA | 1 |
| Otero-Espinar, FJ | 1 |
| Briones, VG | 1 |
| Seidel, K | 1 |
| Tietze, LF | 1 |
| Braun, C | 1 |
| Mann, M | 1 |
| Kerschnitzki, A | 1 |
| Tietze, JK | 1 |
| Issa, NT | 1 |
| Kircik, L | 1 |
| Wang, Y | 1 |
| Lipner, SR | 3 |
| Endringer Pinto, F | 1 |
| Bagger, C | 1 |
| Kunze, G | 1 |
| Joly-Tonetti, N | 1 |
| Thénot, JP | 1 |
| Osman-Ponchet, H | 1 |
| Janfelt, C | 1 |
| Gupta, AK | 11 |
| Venkataraman, M | 1 |
| Shear, NH | 1 |
| Piguet, V | 1 |
| Schaller, M | 4 |
| Sigurgeirsson, B | 1 |
| Sarkany, M | 1 |
| Rich, P | 1 |
| Vlahovic, TC | 1 |
| Joseph, WS | 1 |
| Zane, LT | 3 |
| Hall, SB | 1 |
| Gellings Lowe, N | 1 |
| Adigun, CG | 1 |
| Fabrizi, V | 1 |
| Zacconi, I | 1 |
| Principato, M | 1 |
| Pesca, C | 1 |
| Cruciani, D | 1 |
| Crotti, S | 1 |
| Papini, M | 1 |
| Cutrín Gómez, E | 1 |
| Anguiano Igea, S | 1 |
| Delgado-Charro, MB | 1 |
| Gómez Amoza, JL | 1 |
| Otero Espinar, FJ | 1 |
| Scher, RK | 3 |
| Kline-Schoder, A | 1 |
| Le, Z | 1 |
| Zderic, V | 1 |
| Ko, D | 1 |
| Dhamoon, RK | 1 |
| Popli, H | 1 |
| Gupta, M | 1 |
| Hafeez, F | 1 |
| Hui, X | 2 |
| Selner, M | 1 |
| Rosenthal, B | 1 |
| Maibach, H | 1 |
| Paul, C | 1 |
| Coustou, D | 1 |
| Lahfa, M | 1 |
| Bulai-Livideanu, C | 1 |
| Doss, N | 1 |
| Mokthar, I | 1 |
| Turki, H | 1 |
| Nouira, R | 1 |
| Fazaa, B | 1 |
| Ben Osman, A | 1 |
| Zourabichvili, O | 1 |
| Cazeau, C | 1 |
| Coubetergues, H | 1 |
| Picot, S | 1 |
| Bienvenu, AL | 1 |
| Voisard, JJ | 1 |
| Täuber, A | 2 |
| Müller-Goymann, CC | 2 |
| Lipner, S | 1 |
| Wiederhold, NP | 1 |
| Fothergill, AW | 1 |
| McCarthy, DI | 1 |
| Tavakkol, A | 1 |
| Coronado, D | 2 |
| Merchant, T | 1 |
| Chanda, S | 2 |
| Pajaziti, L | 1 |
| Vasili, E | 1 |
| Seidl, HP | 1 |
| Jäckel, A | 4 |
| Müller, J | 2 |
| Borelli, C | 3 |
| Polak, A | 1 |
| Braunsdorf, C | 1 |
| Mailänder-Sanchez, D | 1 |
| Mulvaney, PM | 1 |
| Telang, GH | 1 |
| Jellinek, N | 1 |
| Hossin, B | 1 |
| Rizi, K | 1 |
| Murdan, S | 1 |
| Shimamura, T | 2 |
| Miyamae, A | 1 |
| Arai, M | 1 |
| Minemura, A | 1 |
| Nozawa, A | 1 |
| Kubota, N | 2 |
| Rosen, T | 3 |
| Stein Gold, LF | 3 |
| Del Rosso, J | 1 |
| Thapa, RK | 1 |
| Choi, JY | 1 |
| Go, TG | 1 |
| Kang, MH | 1 |
| Han, SD | 1 |
| Jun, JH | 1 |
| Son, MW | 1 |
| Yong, CS | 1 |
| Kim, JO | 1 |
| Eichenfield, LF | 1 |
| Friedlander, SF | 1 |
| Carrillo-Muñoz, AJ | 1 |
| Quindós, G | 1 |
| Del Valle, O | 1 |
| Santos, P | 1 |
| Giusiano, G | 1 |
| Guardia, C | 1 |
| Eraso, E | 1 |
| Ezkurra, PA | 1 |
| Tur-Tur, C | 1 |
| Hernández-Molina, JM | 1 |
| Brasch, J | 1 |
| Varga, J | 1 |
| Jensen, JM | 1 |
| Egberts, F | 1 |
| Tintelnot, K | 1 |
| Cathcart, S | 1 |
| Cantrell, W | 1 |
| Elewski, Be | 1 |
| de Berker, D | 1 |
| Baran, R | 6 |
| Tosti, A | 1 |
| Hartmane, I | 1 |
| Altmeyer, P | 1 |
| Hercogova, J | 1 |
| Koudelkova, V | 1 |
| Ruzicka, T | 1 |
| Combemale, P | 1 |
| Mikazans, I | 1 |
| Mayser, P | 1 |
| Freund, V | 1 |
| Budihardja, D | 1 |
| Monti, D | 4 |
| Saccomani, L | 2 |
| Chetoni, P | 2 |
| Burgalassi, S | 2 |
| Senesi, S | 1 |
| Ghelardi, E | 1 |
| Mailland, F | 3 |
| Berger, U | 1 |
| Walker, B | 1 |
| Schmidt, S | 1 |
| Weindl, G | 1 |
| Shemer, A | 1 |
| Nathansohn, N | 1 |
| Trau, H | 1 |
| Amichai, B | 1 |
| Grunwald, MH | 1 |
| Welsh, O | 1 |
| Vera-Cabrera, L | 1 |
| Welsh, E | 1 |
| Traynor, MJ | 1 |
| Turner, RB | 1 |
| Evans, CR | 1 |
| Khengar, RH | 1 |
| Jones, SA | 1 |
| Brown, MB | 1 |
| Subissi, A | 2 |
| Togni, G | 1 |
| Tampucci, S | 1 |
| Nagasaka, S | 1 |
| Suzuki, T | 1 |
| Mukai, H | 1 |
| Shibuya, K | 1 |
| Macura, AB | 1 |
| Krzyściak, P | 1 |
| Skóra, M | 1 |
| Gniadek, A | 1 |
| Herranz, U | 1 |
| Dal Bo, L | 1 |
| Cooper, EA | 1 |
| Cursi, ÍB | 1 |
| Silva, RT | 1 |
| Succi, IB | 1 |
| Bernardes-Engemann, AR | 1 |
| Orofino-Costa, R | 1 |
| Casciano, J | 1 |
| Amaya, K | 1 |
| Doyle, J | 1 |
| Arikian, S | 1 |
| Shear, N | 1 |
| Haspel, M | 1 |
| Kahler, K | 1 |
| Jones, ED | 1 |
| Ryder, JE | 1 |
| Seebacher, C | 2 |
| Epstein, E | 1 |
| Daniel, CR | 1 |
| Daniel, MP | 1 |
| Daniel, J | 1 |
| Sullivan, S | 1 |
| Bell, FE | 1 |
| Reinel, D | 1 |
| Werschler, WP | 1 |
| Bondar, G | 1 |
| Armstrong, D | 1 |
| Albert, SF | 1 |
| Weis, ZH | 1 |
| Sidou, F | 1 |
| Soto, P | 1 |
| Kaoukhov, A | 1 |
| Schouten, JR | 1 |
| Lynch, LE | 1 |
| Marty, JP | 1 |
| Lambert, J | 1 |
| Adjadj, L | 1 |
| Avner, S | 1 |
| Nir, N | 1 |
| Henri, T | 1 |
| Sardana, K | 1 |
| Garg, VK | 1 |
| Manchanda, V | 1 |
| Rajpal, M | 1 |
| Romano, C | 1 |
| Ghilardi, A | 1 |
| Fimiani, M | 1 |
| Torres-Rodríguez, JM | 1 |
| Sellart-Altisent, M | 1 |
| Figueiredo, VT | 1 |
| de Assis Santos, D | 1 |
| Resende, MA | 1 |
| Hamdan, JS | 1 |
| Wester, RC | 1 |
| Barbadillo, S | 1 |
| Cashmore, AK | 1 |
| Hold, KM | 1 |
| Maibach, HI | 1 |
| Qadripur, SA | 1 |
| Horn, G | 1 |
| Höhler, T | 2 |
| Ulbricht, H | 1 |
| Wörz, K | 1 |
| Cohen, PR | 1 |
| Liony, C | 1 |
| Joly, P | 1 |
| Balguerie, X | 1 |
| Fusade, T | 1 |
| Lauret, P | 1 |
| Rüping, KW | 1 |
| Haas, PJ | 1 |
| Effendy, I | 1 |
| Kolczak, H | 1 |
| Ossowski, B | 1 |
| Van Doorslaer, EK | 1 |
| Tormans, G | 1 |
| Van Rossem, K | 1 |
| Eggleston, A | 1 |
| Dubois, DJ | 1 |
| De Doncker, P | 1 |
| Haneke, E | 1 |
| Ploysangam, T | 1 |
| Lucky, AW | 1 |
| Bohn, M | 1 |
| Kraemer, KT | 1 |
| Fleckman, P | 1 |
| Yang, D | 1 |
| Michel, L | 1 |
| Chaumont, JP | 1 |
| Millet-Clerc, J | 1 |
| Nietsch, KH | 1 |
| Ulbricht, HM | 1 |
| Galitz, J | 1 |
| Ceschin-Roques, CG | 1 |
| Hänel, H | 1 |
| Pruja-Bougaret, SM | 1 |
| Luc, J | 1 |
| Vandermander, J | 1 |
| Michel, G | 1 |
| Yu, B | 1 |
| Zhou, G | 1 |
| Wang, B | 2 |
| Ben, Y | 1 |
| Yan, H | 1 |
| Shao, Y | 1 |
| Dompmartin, D | 1 |
| Dompmartin, A | 1 |
| Deluol, AM | 1 |
| Coulaud, JP | 1 |
| Rollman, O | 1 |
| Johansson, S | 1 |
| Jue, SG | 1 |
| Dawson, GW | 1 |
| Brogden, RN | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparison of Effectiveness of Topical Amphotericin B in 30% Dimethylsulphoxide and 30% Dimethylsulphoxide in Treating of Non-dermatophytes Onychomycosis: Randomized Double Blind Controlled Trial Pilot Study[NCT03814343] | Phase 4 | 19 participants (Actual) | Interventional | 2019-01-15 | Completed | ||
| A Placebo Controlled, Randomized, Prospective Study to Evaluate the Efficacy and Safety of PinPointe FootLaser in Patients Who Have Failed Oral Terbinafine Treatment for Onychomycosis[NCT01920178] | 7 participants (Actual) | Interventional | 2013-04-30 | Terminated (stopped due to Financial support of the Study withdrawn by Nuvolase, Inc ( PinPointe FootLaser) due to delayed start of the Study and inadequate subjects enrolled) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT01920178)
Timeframe: 12 months
| Intervention | participants (Number) |
|---|---|
| PinPointe Foot Laser | 0 |
| Sham Laser Group | 0 |
26 reviews available for ciclopirox and Nail Fungus
| Article | Year |
|---|---|
Individual Article: Updated Review of Topical Pharmaceuticals and Complementary and Alternative Medications for the Treatment of Onychomycosis in Both General and Special Populations in the United States.
Topics: Ciclopirox; Humans; Onychomycosis; Pharmaceutical Preparations; Quality of Life; United States | 2023 |
Onychomycosis in children - review on treatment and management strategies.
Topics: Administration, Topical; Adult; Antifungal Agents; Child; Ciclopirox; Humans; Onychomycosis; Terbina | 2022 |
Onychomycosis: Treatment and prevention of recurrence.
Topics: Antifungal Agents; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Ciclopirox; Fluconazole | 2019 |
Novel Drug Delivery Strategies for the Treatment of Onychomycosis.
Topics: Administration, Topical; Antifungal Agents; Ciclopirox; Drug Carriers; Humans; Liposomes; Morpholine | 2019 |
Antifungal agents for onychomycosis: new treatment strategies to improve safety.
Topics: Administration, Oral; Administration, Topical; Antifungal Agents; Boron Compounds; Bridged Bicyclo C | 2016 |
Pediatric Onychomycosis: The Emerging Role of Topical Therapy.
Topics: Administration, Topical; Adult; Age Factors; Antifungal Agents; Child; Ciclopirox; Family; Humans; I | 2017 |
Onychomycosis and diabetes.
Topics: Administration, Topical; Antifungal Agents; Ciclopirox; Diabetes Complications; Humans; Morpholines; | 2009 |
Clinical practice. Fungal nail disease.
Topics: Administration, Oral; Administration, Topical; Aged; Antifungal Agents; Ciclopirox; Debridement; Dia | 2009 |
Toenail onychomycosis in diabetic patients: issues and management.
Topics: Administration, Oral; Administration, Topical; Antifungal Agents; Ciclopirox; Comorbidity; Diabetes | 2009 |
Onychomycosis.
Topics: Administration, Cutaneous; Administration, Oral; Antifungal Agents; Ciclopirox; Drug Administration | 2010 |
Ciclopirox: recent nonclinical and clinical data relevant to its use as a topical antimycotic agent.
Topics: Administration, Topical; Animals; Anti-Bacterial Agents; Antifungal Agents; Candidiasis; Ciclopirox; | 2010 |
Economic analysis of oral and topical therapies for onychomycosis of the toenails and fingernails.
Topics: Adult; Antifungal Agents; Ciclopirox; Cost-Benefit Analysis; Drug Costs; Economics, Pharmaceutical; | 2003 |
The use of topical therapies to treat onychomycosis.
Topics: Administration, Cutaneous; Antifungal Agents; Ciclopirox; Humans; Morpholines; Onychomycosis; Pyrido | 2003 |
Assessing treatment outcomes in toenail onychomycosis clinical trials.
Topics: Antifungal Agents; Ciclopirox; Clinical Trials as Topic; Foot Dermatoses; Humans; Itraconazole; Naph | 2004 |
Management of onychomycosis with topicals.
Topics: Administration, Topical; Antifungal Agents; Ciclopirox; Foot Dermatoses; Humans; Onychomycosis; Pyri | 2004 |
Topical antifungal drugs for the treatment of onychomycosis: an overview of current strategies for monotherapy and combination therapy.
Topics: Administration, Oral; Administration, Topical; Antifungal Agents; Ciclopirox; Clinical Trials as Top | 2005 |
Ciclopirox nail lacquer 8% for the treatment of onychomycosis: a Canadian perspective.
Topics: Antifungal Agents; Canada; Ciclopirox; Humans; Onychomycosis; Pyridones; Treatment Outcome | 2005 |
Topical and surgical treatment of onychomycosis.
Topics: Administration, Topical; Antifungal Agents; Ciclopirox; Combined Modality Therapy; Debridement; Foot | 1994 |
Childhood white superficial onychomycosis caused by Trichophyton rubrum: report of seven cases and review of the literature.
Topics: Allylamine; Antifungal Agents; Child; Child, Preschool; Ciclopirox; Coloring Agents; Female; Foot De | 1997 |
Dermatopharmacology of ciclopirox nail lacquer topical solution 8% in the treatment of onychomycosis.
Topics: Administration, Topical; Animals; Antifungal Agents; Cattle; Ciclopirox; Clinical Trials as Topic; D | 2000 |
Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis.
Topics: Administration, Topical; Adult; Aged; Analysis of Variance; Antifungal Agents; Ciclopirox; Clinical | 2000 |
Ciclopirox nail lacquer solution 8% in the 21st century.
Topics: Administration, Topical; Antifungal Agents; Ciclopirox; Foot Dermatoses; Forecasting; Humans; Onycho | 2000 |
Pharmacoeconomic analysis of ciclopirox nail lacquer solution 8% and the new oral antifungal agents used to treat dermatophyte toe onychomycosis in the United States.
Topics: Administration, Oral; Administration, Topical; Antifungal Agents; Arthrodermataceae; Ciclopirox; Cos | 2000 |
Ciclopirox nail lacquer: a brush with onychomycosis.
Topics: Administration, Topical; Antifungal Agents; Ciclopirox; Clinical Trials as Topic; Humans; Onychomyco | 2001 |
Treatment of dermatophyte toenail onychomycosis in the United States. A pharmacoeconomic analysis.
Topics: Administration, Topical; Antifungal Agents; Ciclopirox; Drug Costs; Foot Dermatoses; Griseofulvin; H | 2002 |
Ciclopirox olamine 1% cream. A preliminary review of its antimicrobial activity and therapeutic use.
Topics: Animals; Antifungal Agents; Candidiasis, Cutaneous; Candidiasis, Vulvovaginal; Ciclopirox; Dermatomy | 1985 |
13 trials available for ciclopirox and Nail Fungus
| Article | Year |
|---|---|
Efficacy and safety of a new medicated nail hydrolacquer in the treatment of adults with toenail onychomycosis: A randomised clinical trial.
Topics: Administration, Topical; Adult; Antifungal Agents; Ciclopirox; Foot Dermatoses; Humans; Nails; Onych | 2023 |
Patient-reported outcomes from two randomised studies comparing once-weekly application of amorolfine 5% nail lacquer to other methods of topical treatment in distal and lateral subungual onychomycosis.
Topics: Administration, Topical; Adult; Aged; Antifungal Agents; Ciclopirox; Drug Administration Schedule; F | 2017 |
A multicenter, randomized, open-label, controlled study comparing the efficacy, safety and cost-effectiveness of a sequential therapy with RV4104A ointment, ciclopiroxolamine cream and ciclopirox film-forming solution with amorolfine nail lacquer alone in
Topics: Adolescent; Adult; Aged; Antifungal Agents; Ciclopirox; Cost-Benefit Analysis; Drug Combinations; Dr | 2013 |
Treatment of Onychomycosis - a Clinical Study.
Topics: Antifungal Agents; Ciclopirox; Drug Administration Schedule; Drug Therapy, Combination; Fluconazole; | 2015 |
An innovative water-soluble biopolymer improves efficacy of ciclopirox nail lacquer in the management of onychomycosis.
Topics: Adult; Antifungal Agents; Biopolymers; Ciclopirox; Female; Humans; Male; Middle Aged; Onychomycosis; | 2009 |
Nail penetration and predicted mycological efficacy of an innovative hydrosoluble ciclopirox nail lacquer vs. a standard amorolfine lacquer in healthy subjects.
Topics: Adult; Ciclopirox; Humans; Male; Middle Aged; Morpholines; Nails; Onychomycosis; Pyridones; Referenc | 2013 |
Comparison of visual assessments versus planimetry assessments in a large-scale clinical trial of onychomycosis.
Topics: Antifungal Agents; Ciclopirox; Diagnosis, Computer-Assisted; Foot Dermatoses; Humans; Naphthalenes; | 2014 |
A randomized comparison of nail surface remanence of three nail lacquers, containing amorolfine 5%, ciclopirox 8% or tioconazole 28%, in healthy volunteers.
Topics: Adult; Antifungal Agents; Ciclopirox; Female; Humans; Imidazoles; Lacquer; Male; Morpholines; Nails; | 2004 |
Combination of oral terbinafine and topical ciclopirox compared to oral terbinafine for the treatment of onychomycosis.
Topics: Administration, Oral; Administration, Topical; Adult; Antifungal Agents; Ciclopirox; Drug Therapy, C | 2005 |
[On the local efficacy of ciclopiroxolamine in onychomycoses (author's transl)].
Topics: Adolescent; Adult; Aged; Antifungal Agents; Ciclopirox; Clinical Trials as Topic; Female; Humans; Ma | 1981 |
[Therapy with ciclopirox lacquer of onychomycoses caused by molds].
Topics: Administration, Topical; Antifungal Agents; Ciclopirox; Follow-Up Studies; Humans; Lacquer; Onychomy | 1994 |
[Treatment onychomycoses--bifonazole nail set in comparison with urea with ciclopiroxolamine formulation].
Topics: Administration, Topical; Adult; Aged; Antifungal Agents; Ciclopirox; Female; Humans; Male; Middle Ag | 1993 |
A multicenter, open-label study of the efficacy and safety of ciclopirox nail lacquer solution 8% for the treatment of onychomycosis in patients with diabetes.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antifungal Agents; Ciclopirox; Diabetes Com | 2001 |
63 other studies available for ciclopirox and Nail Fungus
| Article | Year |
|---|---|
Discovery of a new boron-containing antifungal agent, 5-fluoro-1,3-dihydro-1-hydroxy-2,1- benzoxaborole (AN2690), for the potential treatment of onychomycosis.
Topics: Administration, Topical; Antifungal Agents; Aspergillus fumigatus; Boron Compounds; Bridged Bicyclo | 2006 |
Reactive oxygen and nitrogen species are crucial for the antifungal activity of amorolfine and ciclopirox olamine against the dermatophyte Trichophyton interdigitale.
Topics: Animals; Antifungal Agents; Arthrodermataceae; Ciclopirox; Ergosterol; Microbial Sensitivity Tests; | 2022 |
Bacterial nanocellulose patches as a carrier for hydrating formulations to improve the topical treatment of nail diseases.
Topics: Administration, Topical; Antifungal Agents; Ciclopirox; Excipients; Glycerol; Humans; Nail Diseases; | 2022 |
Evaluation of the heat sensitivity of Trichophyton rubrum and Trichophyton interdigitale.
Topics: Ciclopirox; Hot Temperature; Humans; Onychomycosis; Powders; Trichophyton | 2023 |
Retrospective analysis of adverse events with topical onychomycosis medications reported to the United States Food and Drug Administration.
Topics: Administration, Topical; Adverse Drug Reaction Reporting Systems; Antifungal Agents; Boron Compounds | 2020 |
Visualisation of penetration of topical antifungal drug substances through mycosis-infected nails by matrix-assisted laser desorption ionisation mass spectrometry imaging.
Topics: Administration, Topical; Allylamine; Antifungal Agents; Ciclopirox; Humans; Lacquer; Morpholines; Na | 2020 |
Clinical trial designs for topical antifungal treatments of onychomycosis and implications on clinical practice.
Topics: Administration, Cutaneous; Antifungal Agents; Boron Compounds; Bridged Bicyclo Compounds, Heterocycl | 2017 |
Toenail onychomycosis by Trichophyton rubrum and concurrent infestation with Tyrophagus putrescentiae.
Topics: Aged; Agricultural Workers' Diseases; Animal Husbandry; Antifungal Agents; Ciclopirox; Diabetes Mell | 2017 |
Microstructural alterations in the onychomycotic and psoriatic nail: Relevance in drug delivery.
Topics: Administration, Topical; Adult; Antifungal Agents; Ciclopirox; Clobetasol; Foot Dermatoses; Healthy | 2018 |
Ultrasound-Enhanced Ciclopirox Delivery for Treatment of Onychomycosis.
Topics: Administration, Topical; Antifungal Agents; Ciclopirox; Humans; Nails; Onychomycosis; Permeability; | 2018 |
Optimizing topical therapy for onychomycosis: the importance of patient education.
Topics: Administration, Topical; Antifungal Agents; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic | 2018 |
Ciclopirox delivery into the human nail plate using novel lipid diffusion enhancers.
Topics: Absorption, Physicochemical; Administration, Topical; Antifungal Agents; Cadaver; Ciclopirox; Dose-R | 2014 |
Comparison of the antifungal efficacy of terbinafine hydrochloride and ciclopirox olamine containing formulations against the dermatophyte Trichophyton rubrum in an infected nail plate model.
Topics: Animals; Antifungal Agents; Arthrodermataceae; Cattle; Chemistry, Pharmaceutical; Ciclopirox; Foot D | 2014 |
Onychomycosis: current and future therapies.
Topics: Antifungal Agents; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Ciclopirox; Debridement | 2014 |
Luliconazole demonstrates potent in vitro activity against dermatophytes recovered from patients with onychomycosis.
Topics: Antifungal Agents; Arthrodermataceae; Ciclopirox; Dermatomycoses; Humans; Imidazoles; Microbial Sens | 2014 |
In Vitro Nail Penetration and Antifungal Activity of Tavaborole, a Boron-Based Pharmaceutical.
Topics: Administration, Topical; Antifungal Agents; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic | 2015 |
Sporicidal effect of amorolfine and other antimycotics used in the therapy of fungal nail infections.
Topics: Antifungal Agents; Candida albicans; Ciclopirox; Epidermophyton; Fluconazole; Hand Dermatoses; Human | 2015 |
Comparison of user-friendliness and treatment cost of Loceryl® vs. Ciclopoli®--a patient's perspective.
Topics: Administration, Topical; Adult; Antifungal Agents; Ciclopirox; Foot Dermatoses; Germany; Health Care | 2015 |
Trichophytum rubrum endonyx onychomycosis resistant to standard oral and topical therapies.
Topics: Administration, Cutaneous; Administration, Oral; Antifungal Agents; Ciclopirox; Drug Resistance, Mul | 2015 |
Application of Hansen Solubility Parameters to predict drug-nail interactions, which can assist the design of nail medicines.
Topics: Adolescent; Adult; Antifungal Agents; Ciclopirox; Drug Interactions; Female; Humans; Keratins; Male; | 2016 |
[Distribution of Luliconazole in Nail Plate by In Vitro Permeation and Efficacy by Zone of Inhibition Test after Treatment of Luliconazole Nail Solution].
Topics: Administration, Topical; Antifungal Agents; Ciclopirox; Dose-Response Relationship, Drug; Drug Resis | 2016 |
In vitro evaluation of the antifungal efficacy of poloxamer 407-based formulations in an infected nail plate model.
Topics: Administration, Topical; Animals; Antifungal Agents; Cattle; Chemistry, Pharmaceutical; Ciclopirox; | 2016 |
Antifungal Drugs for Onychomycosis: Efficacy, Safety, and Mechanisms of Action.
Topics: Administration, Cutaneous; Administration, Oral; Antifungal Agents; Boron Compounds; Bridged Bicyclo | 2016 |
Introduction.
Topics: Administration, Cutaneous; Antifungal Agents; Boron Compounds; Bridged Bicyclo Compounds, Heterocycl | 2016 |
Using Topical Antifungal Medications: Instructions for patients.
Topics: Administration, Cutaneous; Antifungal Agents; Boron Compounds; Bridged Bicyclo Compounds, Heterocycl | 2016 |
Development of ciclopirox nail lacquer with enhanced permeation and retention.
Topics: Administration, Topical; Animals; Antifungal Agents; Cattle; Ciclopirox; Hoof and Claw; Humans; Lacq | 2016 |
In vitro antifungal activity of sertaconazole nitrate against recent isolates of onychomycosis causative agents.
Topics: Antifungal Agents; Arthrodermataceae; Ciclopirox; Dose-Response Relationship, Drug; Fluconazole; Fun | 2008 |
Nail infection by Aspergillus ochraceopetaliformis.
Topics: Antifungal Agents; Aspergillus; Ciclopirox; Female; Foot Dermatoses; Humans; Middle Aged; Naphthalen | 2009 |
Hydrosoluble medicated nail lacquers: in vitro drug permeation and corresponding antimycotic activity.
Topics: Absorption; Administration, Topical; Animals; Antifungal Agents; Cattle; Ciclopirox; Hoof and Claw; | 2010 |
Susceptibility testing of amorolfine, bifonazole and ciclopiroxolamine against Trichophyton rubrum in an in vitro model of dermatophyte nail infection.
Topics: Administration, Topical; Antifungal Agents; Ciclopirox; Humans; Imidazoles; Microbial Sensitivity Te | 2009 |
Ciclopirox nail lacquer for the treatment of onychomycosis: an open non-comparative study.
Topics: Administration, Topical; Adult; Antifungal Agents; Ciclopirox; Female; Foot Dermatoses; Humans; Lacq | 2010 |
Effect of a novel penetration enhancer on the ungual permeation of two antifungal agents.
Topics: Adenosine Triphosphate; Administration, Topical; Antifungal Agents; Cadaver; Ciclopirox; Humans; In | 2010 |
Validation of bovine hoof slices as a model for infected human toenails: in vitro ciclopirox transungual permeation.
Topics: Administration, Topical; Animals; Antifungal Agents; Cattle; Ciclopirox; Disease Models, Animal; Hoo | 2011 |
Establishment of a novel model of onychomycosis in rabbits for evaluation of antifungal agents.
Topics: Animals; Antifungal Agents; Ciclopirox; Lacquer; Male; Models, Biological; Morpholines; Onychomycosi | 2011 |
Case report: onychomycosis due to Trichophyton schoenleinii.
Topics: Antifungal Agents; Ciclopirox; Foot Dermatoses; Humans; Male; Middle Aged; Mycological Typing Techni | 2012 |
[When the nail is the polished one].
Topics: Administration, Topical; Antifungal Agents; Ciclopirox; Combined Modality Therapy; Disease Progressi | 2012 |
Onychomycosis due to Neoscytalidium treated with oral terbinafine, ciclopirox nail lacquer and nail abrasion: a pilot study of 25 patients.
Topics: Administration, Oral; Administration, Topical; Ascomycota; Ciclopirox; Debridement; Female; Humans; | 2013 |
Onychomycosis: current treatment options.
Topics: Antifungal Agents; Ciclopirox; Female; Humans; Itraconazole; Male; Middle Aged; Onychomycosis; Patie | 2003 |
I've heard there's a nail polish for nail fungus. Does it work?
Topics: Administration, Topical; Antifungal Agents; Ciclopirox; Humans; Onychomycosis; Pyridones | 2003 |
Action mechanisms of modern antifungal agents and resulting problems in the management of onychomycosis.
Topics: Antifungal Agents; Ciclopirox; Combined Modality Therapy; Humans; Microbial Sensitivity Tests; Micro | 2003 |
Fungus-free versus disease-free nails.
Topics: Antifungal Agents; Ciclopirox; Humans; Onychomycosis; Pyridones; Remission Induction | 2004 |
Managing simple chronic paronychia and onycholysis with ciclopirox 0.77% and an irritant-avoidance regimen.
Topics: Administration, Topical; Adolescent; Adult; Aged; Aged, 80 and over; Antifungal Agents; Chronic Dise | 2004 |
[Onychomycosis].
Topics: Antifungal Agents; Ciclopirox; Debridement; Diagnosis, Differential; Drug Therapy, Combination; Fluc | 2004 |
Treatment costs of three nail lacquers used in onychomycosis.
Topics: Adult; Antifungal Agents; Ciclopirox; Drug Costs; Europe; Female; Foot Dermatoses; Hand Dermatoses; | 2005 |
Congenital candidal onychomycoses: effective cure with ciclopirox olamine 8% nail lacquer.
Topics: Administration, Topical; Antifungal Agents; Candidiasis; Ciclopirox; Hand Dermatoses; Humans; Infant | 2006 |
Dystrophic onychomycosis due to Microsporum gypseum.
Topics: Adult; Ciclopirox; Female; Humans; Microsporum; Naphthalenes; Onychomycosis; Pyridones; Terbinafine | 2006 |
[Bilateral proximal cellulitis and onychomycosis in both big toes due to Fusarium solani].
Topics: Antifungal Agents; Cellulitis; Ciclopirox; Diabetes Mellitus, Type 2; Disease Susceptibility; Drug R | 2006 |
Identification and in vitro antifungal susceptibility testing of 200 clinical isolates of Candida spp. responsible for fingernail infections.
Topics: Antifungal Agents; Brazil; Candida; Candidiasis; Ciclopirox; Fluconazole; Hand Dermatoses; Humans; I | 2007 |
In Vitro penetration of a novel oxaborole antifungal (AN2690) into the human nail plate.
Topics: Antifungal Agents; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Chemistry, Pharmaceutic | 2007 |
[Cutaneous and nail infections caused by Hendersonula toruloidea].
Topics: Adult; Antifungal Agents; Ciclopirox; Dermatomycoses; Diagnosis, Differential; Female; Hand Dermatos | 1993 |
[Onychomycoses--therapeutic challenge for physician and patient. Report from the MYK 92 26th Scientific Meeting of the German-speaking Mycology Association. Graz, 4 September 1992].
Topics: Antifungal Agents; Ciclopirox; Humans; Onychomycosis; Pyridones | 1993 |
[Topical therapy of onychomycoses with 8% ciclopirox laquer. An open, non-comparative study].
Topics: Administration, Topical; Adult; Aged; Antifungal Agents; Ciclopirox; Female; Humans; Male; Middle Ag | 1993 |
Economic evaluation of antifungal agents in the treatment of toenail onychomycosis in Germany.
Topics: Algorithms; Antifungal Agents; Ciclopirox; Cost-Benefit Analysis; Costs and Cost Analysis; Decision | 1996 |
[Hydroxy pyridone as antimycotic agent].
Topics: Adult; Age Factors; Antifungal Agents; Ciclopirox; Humans; Infant; Infant, Newborn; Onychomycosis; P | 1996 |
Ciclopirox (Penlac) nail lacquer for onychomycosis.
Topics: Antifungal Agents; Ciclopirox; Clinical Trials as Topic; Dose-Response Relationship, Drug; Erythema; | 2000 |
Ciclopirox nail lacquer topical solution 8%.
Topics: Administration, Topical; Antifungal Agents; Ciclopirox; Clinical Trials as Topic; Humans; Onychomyco | 2000 |
Use of caryophyllene oxide as an antifungal agent in an in vitro experimental model of onychomycosis.
Topics: Animals; Antifungal Agents; Ciclopirox; Hoof and Claw; Humans; Imidazoles; Onychomycosis; Polycyclic | 1999 |
Successful treatment of onychomycosis with ciclopirox nail lacquer: a case report.
Topics: Administration, Topical; Aged; Antifungal Agents; Ciclopirox; Foot Dermatoses; Humans; Male; Onychom | 2001 |
[New treatments of onychomycoses].
Topics: Administration, Topical; Antifungal Agents; Candidiasis; Ciclopirox; Fluconazole; Foot Dermatoses; H | 1992 |
Ciclopirox nail lacquer 8%: in vivo penetration into and through nails and in vitro effect on pig skin.
Topics: Administration, Topical; Animals; Antifungal Agents; Biological Transport; Candida; Ciclopirox; Cosm | 1991 |
A clinical and laboratory study of ciclopirox olamine (8% Batrafen) in the treatment of onychomycosis.
Topics: Adult; Aged; Antifungal Agents; Candida albicans; Ciclopirox; Female; Foot Dermatoses; Hand Dermatos | 1991 |
Onychomycosis and AIDS: treatment with topical ciclopirox olamine.
Topics: Acquired Immunodeficiency Syndrome; Administration, Topical; Antifungal Agents; Ciclopirox; Hand Der | 1990 |
Hendersonula toruloidea infection: successful response of onychomycosis to nail avulsion and topical ciclopiroxolamine.
Topics: Administration, Cutaneous; Adult; Antifungal Agents; Ciclopirox; Hand Dermatoses; Humans; Male; Mito | 1987 |